Assessment of efficacy of vardenafil in subjects with erectile dysfunction and diabetes, hypertension or...
Date First Received: April 24, 2008
Last Updated: June 19, 2009
Verified by: Bayer, June 2009
Clinical Trial Phase: Phase 3 | Start Date: December 2003
Overall Status: Completed
Estimated Enrollment: 530
Brief Summary
Official Title: “A Randomized, Open-Label, Multi-Center, Parallel Group Study to Investigate the Efficacy and Safety of Vardenafil in Comparison to Tadalafil in Males With Erectile Dysfunction and a Diagnosis of Diabetes, Hypertension or Hyperlipidemia”
Condition Keyword(s):
Intervention(s):
Assessment of efficacy of vardenafil in subjects with erectile dysfunction and diabetes, hypertension or hyperlipidemia
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Intervention(s) in this Clinical Trial
- Drug: Levitra (Vardenafil, BAY38-9456)
- 10 mg one hour prior to sexual intercourse
- Drug: Tadalafil
- 10 mg taken approximately 24 hours prior to sexual intercourse
Arms, Groups and Cohorts in this Clinical Trial
- Experimental: Arm 1
- Active Comparator: Arm 2
Outcome Measures for this Clinical Trial
Primary Measures
- Sexual encounter profile question 3 observed within 15 minutes to 4 hours for vardenafil and 22 to 26 hours for the tadalafil group
- Time Frame: 4 weeks
Safety Issue?: No
- Time Frame: 4 weeks
Secondary Measures
- Sexual encounter profile question 2
- Time Frame: 4 weeks
Safety Issue?: No
- Time Frame: 4 weeks
- Hardness of erection
- Time Frame: 4 weeks
Safety Issue?: No
- Time Frame: 4 weeks
- Other diary based variables
- Time Frame: 4 weeks
Safety Issue?: No
- Time Frame: 4 weeks
- Safety and tolerability
- Time Frame: 4 weeks
Safety Issue?: Yes
- Time Frame: 4 weeks
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Age: 18 years and older
- Males with erectile dysfunction
- Stable heterosexual relationship
- Medical history / diagnosis of diabetes mellitus and/or hypertension and/or hyperlipidemia
Exclusion Criteria:
- Primary hypoactive sexual desire
- History of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months
- Nitrate use
- Other exclusion criteria apply according to Summary of Product Characteristics
Gender Eligibility for this Clinical Trial: Male
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Bayer
Overall Clinical Trial Officials and Contacts
Bayer Study Director Study Director Bayer
Additional Information
Information obtained from ClinicalTrials.gov on July 02, 2009
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00668109
Study ID Number: 10893
ClinicalTrials.gov Identifier: NCT00668109
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
Click here to find results for studies related to marketed products
Click here and search for drug information provided by the FDA
Click here and search for information on any recalls, market or product safety alerts by the FDA
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.